Oragenics Inc. and Aragen Bioscience Enter Agreement to Accelerate Development of TerraCoV2, a COVID 19 Vaccine Candidate (Market Insider)

Oragenics Inc. and Aragen Bioscience Enter Agreement to Accelerate Development of TerraCoV2, a COVID 19 Vaccine Candidate

UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced that through its wholly-owned subsidiary, Noachis Terra, it has entered into an agreement with Aragen Bioscience, a leading contract research organization focused on accelerating pre-clinical biologics product development, to advance TerraCov2 the Company’s SARS CoV-2 vaccine candidate. Under the terms of the agreement, Aragen will provide cell line development services to Oragenics to aid in the development of Oragenics’ TerraCoV2, which could provide specific immunity from COVID-19.

Learn more about Oragenics Inc. and Aragen Bioscience Enter Agreement to Accelerate Development of TerraCoV2, a COVID 19 Vaccine Candidate.
X